MiNK Therapeutics Inc. (INKT)
NASDAQ: INKT
· Real-Time Price · USD
7.60
0.20 (2.70%)
At close: May 02, 2025, 3:48 PM
7.96
4.74%
After-hours: May 02, 2025, 04:05 PM EDT
Company Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
The company was formerly known as AgenTus Therapeutics, Inc.
MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
MiNK Therapeutics Inc.
| Country | United States |
| IPO Date | Oct 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Dr. Jennifer S. Buell Ph.D. |
Contact Details
Address: 149 Fifth Avenue New York, New York United States | |
| Website | https://minktherapeutics.com |
Stock Details
| Ticker Symbol | INKT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840229 |
| CUSIP Number | 603693102 |
| ISIN Number | US6036931029 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer S. Buell Ph.D. | President, Chief Executive Officer & Director |
| Christine M. Klaskin | Treasurer and Principal Financial & Accounting Officer |
| Dr. Garo H. Armen Ph.D. | Executive Chairman |
| Eleni Chantzoura Ph.D. | Director & Head of Discovery |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Filing |
| Apr 18, 2025 | PRE 14A | Filing |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4 | Filing |
| Mar 05, 2025 | 4 | Filing |